Also trades as: 0K1R.L (LSE) · $vol 0M
VRDN NASDAQ
Viridian Therapeutics, Inc.
1W: +1.7%
1M: +9.0%
3M: +44.5%
YTD: -36.4%
1Y: +12.9%
3Y: -4.8%
5Y: +17.2%
$19.51
-0.19 (-0.96%)
Weekly Expected Move ±7.3%
$16
$18
$19
$21
$22
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$20.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.8B
52W Range13.18-34.29
Volume1,060,762
Avg Volume2,561,564
Beta0.90
Dividend—
Analyst Ratings
Company Info
CEOStephen F. Mahoney
Employees252
SectorHealthcare
IndustryBiotechnology
IPO Date2014-06-18
Websiteviridiantherapeutics.com
221 Crescent Street
Waltham, MA 02453
US
Waltham, MA 02453
US
617 272 4600
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Latest News
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
Viridian launches first commercial product as U.S. approves thyroid eye disease therapy
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million
Viridian Therapeutics prices upsized $350M concurrent stock, and convertible notes offerings
12 Health Care Stocks Moving In Tuesday's Intraday Session
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| CAIN CHRISTOPHER W. | A-Award | 32,341 | $18.48 | 2026-07-01 |
| Ajer Jeffrey Robert | A-Award | 32,341 | $18.48 | 2026-07-01 |
| Moses Jennifer K. | A-Award | 32,341 | $18.48 | 2026-07-01 |
| Gheuens Sarah | A-Award | 32,341 | $18.48 | 2026-07-01 |
| Kiselak Tomas | A-Award | 32,341 | $18.48 | 2026-07-01 |